Skip to main content

Advertisement

Log in

Anti-MAG IgM: differences in antibody tests and correlation with clinical findings

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Objectives

Anti-myelin-associated glycoprotein (MAG) antibody is associated with clinically heterogeneous polyneuropathies. Our purpose was to compare neuropathy phenotypes identified by different anti-MAG tests’ results.

Methods

Cohort study: Sera from 40 neuropathy anti-MAG EIA positive patients were tested for anti-MAG by Western blot (WB), for anti-peripheral nerve myelin (PNM) on monkey nerve by immunofluorescence assay (IFA), and for anti-HNK1 on rat CNS slices by IFA. Anti-sulfatide antibodies, for comparison, were also tested by EIA.

Results

Among 40 anti-MAG EIA positive sera, 85% also had anti-PNM IFA reactivity and 67.5% bind HNK1 on rat CNS. Anti-HNK1 positive patients had the classical predominantly distal acquired demyelinating symmetric (DADS) neuropathy with a benign course, while anti-PNM positive but anti-HNK1 negative patients had predominantly axonal neuropathy with a high frequency of anti-sulfatide reactivity and the worst long-term prognosis. Anti-MAG EIA positive patients without anti-PNM or anti-HNK1 IFA reactivity had a CIDP-like polyneuropathy.

Conclusion

Different methods to test for anti-MAG antibodies identify different clinical and electrophysiological findings, as well as long-term outcome. HNK1 reactivity is the strongest marker of DADS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Abbreviations

MAG:

Myelin-associated glycoprotein

EIA:

Enzyme immunosorbent assay

IFA:

Immunofluorescence assay

WB:

Western blot

HNK1:

Human natural killer-1

DADS:

Distal acquired demyelinating symmetric neuropathy

CIDP:

Chronic inflammatory demyelinating polyneuropathy

PNM:

Peripheral nerve myelin

SGPG:

Sulfate-3-glucuronyl paragloboside

mRD:

Modified Rankin disease

IVIg:

Intravenous immunoglobulin

PE:

Plasma exchange

MCV:

Motor conduction velocity

DL:

Distal latency

CMAP:

Compound motor action potential

SCV:

Sensory conduction velocity

SNAP:

Sensory nerve action potential

References

  1. Nobile-Orazio E, Marmiroli P, Baldini L, Spagnol G, Barbieri S, Moggio M, Polli N, Polli E, Scarlato G (1987) Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 37:1506–1514

    Article  CAS  Google Scholar 

  2. Latov N, Hays AP, Sherman WH (1988) Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 3:301–332

    CAS  PubMed  Google Scholar 

  3. Erb S, Ferracin F, Fuhr P, Rosler KM, Hess CW, Kuntzer T et al (2000) Polyneuropathy attributes: a comparison between patients with anti-MAG and anti-sulfatide antibodies. J Neurol 247:767–772

    Article  CAS  Google Scholar 

  4. Capasso M, Torrieri F, Di Muzio A, De Angelis MV, Lugaresi A, Uncini A (2002) Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy? Clin Neurophysiol 113:346–353

    Article  CAS  Google Scholar 

  5. Ellie E, Vital A, Steck A, Boiron JM, Vital C, Julien J (1996) Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. J Neurol 243:34–43

    Article  CAS  Google Scholar 

  6. Fluri F, Ferracin F, Erne B, Steck AJ (2003) Microheterogeneity of anti-myelin-associated glycoprotein antibodies. J Neurol Sci 207:43–49

    Article  CAS  Google Scholar 

  7. Gorson KC, Ropper AH, Weinberg DH, Weinstein R (2001) Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 24:778–786

    Article  CAS  Google Scholar 

  8. Weiss MD, Dalakas MC, Lauter CJ, Willison HJ, Quarles RH (1999) Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J Neuroimmunol 95:174–184

    Article  CAS  Google Scholar 

  9. Kawagashira Y, Kondo N, Atsuta N, Iijima M, Koike H, Katsuno M, Tanaka F, Kusunoki S, Sobue G (2010) IgM MGUS anti-MAG neuropathy with predominant muscle weakness and extensive muscle atrophy. Muscle Nerve 42:433–435

    Article  Google Scholar 

  10. Magy L, Kaboré R, Mathis S, Lebeau P, Ghorab K, Caudie C et al (2015) Heterogeneity of polyneuropathy associated with anti-MAG antibodies. J Immunol Res 2015:450391

    Article  Google Scholar 

  11. Jaskowski TD, Prince HE, Greer RW, Litwin CM, Hill HR (2007) Further comparisons of assays for detecting MAG IgM autoantibodies. J Neuroimmunol 187:175–178

    Article  CAS  Google Scholar 

  12. Kuijf ML, Eurelings M, Tio-Gillen AP, van Doorn PA, van den Berg LH, Hooijkaas H, Stork J, Notermans NC, Jacobs BC (2009) Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 73:688–695

    Article  CAS  Google Scholar 

  13. Pestronk A, Li F, Griffin J, Feldman EL, Cornblath D, Trotter J, Zhu S, Yee WC, Phillips D, Peeples DM (1991) Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 41:357–362

    Article  CAS  Google Scholar 

  14. Ilyas AA, Cook SD, Dalakas MC, Mithen FA (1992) Anti-MAG IgM paraproteins from some patients with polyneuropathy associated with IgM paraproteinemia also react with sulfatide. J Neuroimmunol 37:85–92

    Article  CAS  Google Scholar 

  15. Ilyas AA, Dalakas MC, Brady RO, Quarles RH (1986) Sulfated glucuronyl glycolipids reacting with anti-myelin-associated glycoprotein monoclonal antibodies including IgM paraproteins in neuropathy: species distribution and partial characterization of epitopes. Brain Res 385:1–9

    Article  CAS  Google Scholar 

  16. Nobile-Orazio E, Giannotta C (2011) Testing for anti-glycolipid IgM antibodies in chronic immune-mediated demyelinating neuropathies. J Peripher Nerv Syst 16(Suppl 1):18–23

    Article  Google Scholar 

  17. Van den Berg L, Hays AP, Nobile-Orazio E, Kinsella LJ, Manfredini E, Corbo M et al (1996) Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve 19:637–643

    Article  Google Scholar 

  18. Matà S, Ambrosini S, Mello T, Lolli F, Minciacchi D (2011) Anti-myelin associated glycoprotein antibodies recognize HNK-1 epitope on CNS. J Neuroimmunol 236:99–105

    Article  Google Scholar 

  19. Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst 15:1–9

    Article  Google Scholar 

  20. Jaskowski TD, Martins TB, Litwin CM, Hill HR (2004) Immunoglobulin (Ig) M antibody against myelin-associated glycoprotein (MAG): a comparison of methods. J Clin Lab Anal 18:247–250

    Article  CAS  Google Scholar 

  21. Pestronk A, Li F, Bieser K, Choksi R, Whitton A, Kornberg AJ, Goldstein JM, Yee WC (1994) Anti-MAG antibodies: major effects of antigen purity and antibody cross-reactivity on ELISA results and clinical correlation. Neurology 44:1131–1137

    Article  CAS  Google Scholar 

  22. Lopate G, Kornberg AJ, Yue J, Choksi R, Pestronk A (2001) Anti-myelin associated glycoprotein antibodies: variability in patterns of IgM binding to peripheral nerve. J Neurol Sci 188:67–72

    Article  CAS  Google Scholar 

  23. Campagnolo M, Ferrari S, Dalla Torre C, Cabrini I, Cacciavillani M, Lucchetta M, Ruggero S, Toffanin E, Cavallaro T, Briani C (2015) Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment. J Neuroimmunol 281:1–4

    Article  CAS  Google Scholar 

  24. Chou DK, Ilyas AA, Evans JE, Costello C, Quarles RH, Jungalwala FB (1986) Structure of sulfated glucuronyl glycolipids in the nervous system reacting with HNK-1 antibody and some IgM paraproteins in neuropathy. J Biol Chem 261:11717–11725

    CAS  PubMed  Google Scholar 

  25. Kruse J, Mailhammer R, Wernecke H, Faissner A, Sommer I, Goridis C et al (1984) Neural cell adhesion molecules and myelin-associated glycoprotein share a common carbohydrate moiety recognized by monoclonal antibodies L2 and HNK-1. Nature 311:153–155

    Article  CAS  Google Scholar 

  26. Yagi H, Yanagisawa M, Suzuki Y, Nakatani Y, Ariga T, Kato K, Yu RK (2010) HNK-1 epitope-carrying tenascin-C spliced variant regulates the proliferation of mouse embryonic neural stem cells. J Biol Chem 285:37293–37301

    Article  CAS  Google Scholar 

  27. Needham LK, Schnaar RL (1993) Carbohydrate recognition in the peripheral nervous system: a calcium-dependent membrane binding site for HNK-1 reactive glycolipids potentially involved in Schwann cell adhesion. J Cell Biol 121:397–408

    Article  CAS  Google Scholar 

  28. Delmont E, Attarian S, Antoine JC, Paul S, Camdessanché JP, Grapperon AM, et al. 2019 Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies. J Neurol 266(8):1973–1979

    Article  CAS  Google Scholar 

  29. Niermeijer JM, Fischer K, Eurelings M, Franssen H, Wokke JH, Notermans NC (2010) Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study. Neurology 74:406–412

    Article  CAS  Google Scholar 

  30. Herrendorff R, Hänggi P, Pfister H, Yang F, Demeestere D, Hunziker F et al (2017) Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy. Proc Natl Acad Sci U S A 114(18):E3689–E3698

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matà Sabrina.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

All procedures involving experiments on human subjects have been done in accordance with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accordance with the Helsinki Declaration of 1975. Specific national laws have been observed.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matà, S., Ambrosini, S., Saccomanno, D. et al. Anti-MAG IgM: differences in antibody tests and correlation with clinical findings. Neurol Sci 41, 365–372 (2020). https://doi.org/10.1007/s10072-019-04089-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-019-04089-7

Keywords

Navigation